


# Author's Accepted Manuscript

## Current Challenges in the Management of Breast Cancer Brain Metastases

Ciara C. O'Sullivan, Nicole N. Davarpanah, Jame Abraham, Susan E. Bates



PII: S0093-7754(17)30061-1  
DOI: <http://dx.doi.org/10.1053/j.seminoncol.2017.06.006>  
Reference: YSONC52002

To appear in: *Seminars in Oncology*

Cite this article as: Ciara C. O'Sullivan, Nicole N. Davarpanah, Jame Abraham and Susan E. Bates, Current Challenges in the Management of Breast Cancer Brain Metastases, *Seminars in Oncology*, <http://dx.doi.org/10.1053/j.seminoncol.2017.06.006>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Current Challenges in the Management of Breast Cancer Brain Metastases

Ciara C. O'Sullivan<sup>1</sup>  
Nicole N. Davarpanah<sup>2</sup>  
Jame Abraham<sup>3</sup>  
Susan E. Bates<sup>4</sup>

<sup>1</sup> Mayo Clinic, Rochester, Minnesota, USA

<sup>2</sup> National Cancer Institute, Bethesda, Maryland, USA

<sup>3</sup> Cleveland Clinic, Ohio, USA

<sup>4</sup> Columbia University Medical Center, New York, New York and J.J. Peters VA Medical Center, Bronx, NY

### Corresponding Author:

Susan E. Bates

Herbert Irving Pavilion, 9th Floor

161 Fort Washington Ave at W. 165th St.

New York, NY

**Tel** - 212 305-5098

**Fax**- 646-317-6271

### Abstract

Approximately 50% of patients with advanced human epidermal growth factor 2 (HER2)-positive breast cancer and triple negative breast cancer (TNBC) ultimately develop breast cancer brain metastases (BCBM), which are associated with significant morbidity and mortality. The advent of HER2-directed therapy resulted in greatly improved survival outcomes, but unfortunately at the price of an increased cumulative incidence of BCBM. We review challenges in the management of BCBM, and potential treatment strategies, including novel agents such as poly-ADP ribose polymerase (PARP) inhibitors (olaparib, veliparib), cyclin dependent kinase 4/6 (CDK4/6) inhibitors

Download English Version:

<https://daneshyari.com/en/article/5530211>

Download Persian Version:

<https://daneshyari.com/article/5530211>

[Daneshyari.com](https://daneshyari.com)